antimalarial market intelligence in cambodia: actwatch ......70% of the market composition was...
Post on 02-Jan-2021
1 Views
Preview:
TRANSCRIPT
0
20
40
60
80
100
Total Public Sector Private for-Profit Health Facility
Pharmacy Itinerant Drug Vendor
Total Private Sector
% O
F A
NT
IMA
LA
RIA
L S
TO
CK
ING
OU
TL
ET
S
2011 2013 2015
Antimalarial Market Intelligence in Cambodia: ACTwatch Findings 2009, 2011, 2013, & 2015
2002: Private sector
social marketing of
ACT & mRDT
2009: MoH bans
artemisinin
monotherapies
2000: ASMQ is
first-line treatment
2010: DHA PPQ is
first-line treatment
2011: Increased private sector
regulation through public
private partnership program
2015: ASMQ is first-line
treatment in areas with
treatment failure
Proportion of outlets stocking a malaria rapid diagnostic test (mRDT):
Availability of mRDT increases over time.
Proportion of outlets with DHA PPQ in stock:
Most antimalarial-stocking outlets had the first-line treatment in stock in 2015.
Market composition:
70% of the market composition was comprised of drug stores, general
retailers, & itinerant drug vendors in 2009, compared to 20% in 2015.
Antimalarial market share:
In 2015, most of the antimalarials distributed were first-line ACT.
In 2009, 20% of the private sector were stocking oral artemisinin
monotherapy, but in 2015, only 1 product was found.
2009 2015
0
20
40
60
80
100
Public Private Public Private Public Private Public Private
2009 2011 2013 2015
MA
RK
ET
SH
AR
E
Public Health Facility
VMW
Private for-Profit
Health Facility
Pharmacy
Drug Store
General Retailer
Itinerant Drug Vendor
0
20
40
60
80
100
Total Public Sector Private for-Profit Health Facility
Pharmacy Itinerant Drug Vendor Total Private Sector
% O
F A
NT
IMA
LA
RIA
L S
TO
CK
ING
OU
TL
ET
S
2009 2011 2013 2015
Non-oral artemisinin monotherapy
Other non-artemisinin therapy
Chloroquine
Oral artemisinin monotherapy
Any ACT
652 (2009); 1,001 (2011); 792 (2013); 858 (2015) = N. of ANTIMALARIAL-STOCKING OUTLETS
2004: Village
Malaria Worker
(VMW) pilot
2011: Eurartesim (DHA
PPQ) receives Stringent
Regulatory Approval
In 2015,
the first-
line ACT
cost
$2.00 &
an mRDT
cost
$1.00
top related